|Awarded On||February 21, 2018|
|Title||Mucosal vaccine formulations for targeted therapy of HPV cancers|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jagannadha Sastry|
|Cancer Sites||Cervix Uteri, Head and Neck, Vagina|
Layperson’s Summary Human papilloma virus (HPV) causes high grade cervical intraepithelial neoplasia (CIN) and invasive cancer that disproportionately affect women in developing countries while HPV associated oral cancers are steadily raising in developed nations. Currently available vaccines based on the HPV protein, L1, are effective for preventing HPV infection but not for treatment of existing HPV infections and cancers, where cancer causing E6/E7 genes are expressed but not the L1. Therapeutic vaccine targeting the HPV E6/E7 genes is an urgent unmet need and may be the only means, especially for underprivileged and economically challenged populations worldwide but equally necessary for...